BIS : ProShares UltraShort Nasdaq Biotechnology

BIS is a Alternative Market Inverse with HIGH fees.

BIS

ProShares UltraShort Nasdaq Biotechnology

FI Score

29 /100

Expense Ratio Rating

5 /10

Expense Rating

1 /10

Market Score

5 /10

Category Score

0 /10

Market Size

5 /10

29% FI Score
  • bis
  • ETF
  • Alternative
  • Inverse

ProShares UltraShort Nasdaq Biotechnology

Expenses: 0.95% (Better than 0% of similar funds)

This is a bad choice for a Inverse Alternative fund. See why »

Fund Summary

The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Largest Holdings

Amount Holding
8.14% Amgen Inc
7.41% Gilead Sciences, Inc
7.21% Vertex Pharmaceuticals Incorporated
6.12% Biogen Inc
5.67% Illumina, Inc
4.13% Regeneron Pharmaceuticals, Inc
3.02% Alexion Pharmaceuticals, Inc
2.25% Seattle Genetics, Inc
2.09% Incyte Corporation
1.91% BioMarin Pharmaceutical Inc

Minafi - The intersection of FI, minimalism & mindfulness.

Don't miss out on new posts, courses, interactive articles and more!

Join & Get Your First Course Free

© 2024   Adam Fortuna

Site Map
Triangle Graduation Cap Angle Down Book regular Phone laptop regular fire regular fire regular search regular Acorn duotone Seedling duotone thumbs down duo